EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+28.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$833M
AUM Growth
+$833M
(+87%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
32.24%
Top 10 Holdings %
Top 10 Hldgs %
55.79%
Holding
71
New
22
Increased
19
Reduced
14
Closed
11
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$58.8M |
| 2 |
AstraZeneca
AZN
|
$39.6M |
| 3 |
United Therapeutics
UTHR
|
$33M |
| 4 |
GSK
GSK
|
$32.8M |
| 5 |
Envista
NVST
|
$29.1M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$18.7M |
| 2 |
Fate Therapeutics
FATE
|
$12.3M |
| 3 |
HSKA
Heska Corp
HSKA
|
$12M |
| 4 |
OraSure Technologies
OSUR
|
$11.4M |
| 5 |
Standard BioTools
LAB
|
$9.68M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Financials | 0.05% |
| 3 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MGLN
26
DELISTED
Magellan Health Services, Inc.
MGLN
| $8.67M | 1.02% |
+104,700
| New | +$8.67M |
|
|
RAD
27
DELISTED
Rite Aid Corporation
RAD
| $8.42M | 0.99% |
+532,004
| New | +$8.42M |
|
28
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.36M | 0.98% |
604,368
+168,373
| +39% | +$2.33M |
|
29
Seres Therapeutics
MCRB
$162M
| $8.18M | 0.96% |
+334,049
| New | +$8.18M |
|
30
QuidelOrtho
QDEL
$1.87B
| $7.29M | 0.86% |
40,583
+31,240
| +334% | +$5.61M |
|
|
AFMD
31
DELISTED
Affimed
AFMD
| $5.61M | 0.66% |
964,707
-280,751
| -23% | -$1.63M |
|
32
Amneal Pharmaceuticals
AMRX
$3B
| $5.38M | 0.63% |
1,178,153
-1,478,055
| -56% | -$6.75M |
|
|
OXFD
33
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $5.37M | 0.63% |
307,742
+14,465
| +5% | +$253K |
|
34
Altimmune
ALT
$325M
| $4.29M | 0.5% |
+380,000
| New | +$4.29M |
|
35
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.66M | 0.43% |
491,852
-651,359
| -57% | -$4.85M |
|
|
FPRX
36
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $3.56M | 0.42% |
+209,155
| New | +$3.56M |
|
37
Sanofi
SNY
$122B
| $3.31M | 0.39% |
68,138
+18,360
| +37% | +$892K |
|
38
HCA Healthcare
HCA
$95.4B
| $2.76M | 0.32% |
16,754
-35,646
| -68% | -$5.86M |
|
39
Prothena Corp
PRTA
$452M
| $2.44M | 0.29% |
203,328
+6,300
| +3% | +$75.7K |
|
40
Carisma Therapeutics
CARM
$15.5M
| $2.11M | 0.25% |
1,559,824
| – | – |
|
41
AnaptysBio
ANAB
$630M
| $1.9M | 0.22% |
+88,334
| New | +$1.9M |
|
42
Surmodics
SRDX
$487M
| $1.8M | 0.21% |
+41,299
| New | +$1.8M |
|
|
ONCT
43
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $1.69M | 0.2% |
+344,090
| New | +$1.69M |
|
|
OTIC
44
DELISTED
Otonomy, Inc.
OTIC
| $1.64M | 0.19% |
253,283
-159,217
| -39% | -$1.03M |
|
|
AUTL
45
Autolus Therapeutics
AUTL
$383M
| $1.39M | 0.16% |
+154,981
| New | +$1.39M |
|
|
CNCE
46
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.31M | 0.15% |
103,829
| – | – |
|
47
Astria Therapeutics
ATXS
$394M
| $1.12M | 0.13% |
+522,042
| New | +$1.12M |
|
48
Exagen
XGN
$213M
| $1.08M | 0.13% |
+81,603
| New | +$1.08M |
|
49
DexCom
DXCM
$30.9B
| $914K | 0.11% |
+2,473
| New | +$914K |
|
50
Protara Therapeutics
TARA
$125M
| $879K | 0.1% |
36,310
| – | – |
|